☆ 3.8 Meeting Abstract

Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

EJC SUPPLEMENTS (2009)

Get Full Text
Add to Collection

Journal

EJC SUPPLEMENTS
Volume 7, Issue 3, Pages 10-10

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S1359-6349(09)72049-X

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.